SIR-Spheres
Commercial- Indications
- Liver cancer
Company intelligence / Profile preview
China Grand Enterprises is a major Chinese investment conglomerate founded in 1993, headquartered in Beijing. It has core business areas in pharmaceuticals/healthcare, trading, property investment, financial services, and more. Its healthcare arm includes ownership of leading pharmaceutical companies such as Grand Pharmaceuticals (China) Co., Ltd., which develops both innovative drugs—such as SIR-Spheres® yttrium‑90 microsphere injections for liver cancer—and traditional Chinese medicine through Lei Yunshang Pharmaceutical Group. The group also operates internationally through brands like Sinclair Global Medical Aesthetics[1][2][3][4].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on China Grand Enterprises.